Intel stock spikes after report of possible US government stake
Robert E. Waltermire, Senior Vice President and Chief Pharma Development Officer at Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company with a market capitalization of $6.39 billion and strong liquidity position (current ratio of 5.98), recently sold 442 shares of the company's common stock. According to InvestingPro analysis, the company maintains robust financial health despite being in its growth phase. The shares were sold at an average price of $273.41 each, totaling approximately $120,847. Following this transaction, Waltermire holds 5,058 shares in the company. The sale was conducted automatically to cover tax withholding obligations related to the vesting of restricted stock units and was not at Waltermire's discretion. The stock has experienced significant volatility recently, with InvestingPro data showing a 13.36% decline over the past week, though analyst targets range from $154 to $530, suggesting diverse views on the company's prospects. Get access to 10+ additional exclusive ProTips and comprehensive analysis through InvestingPro's detailed research reports.
In other recent news, Madrigal Pharmaceuticals reported robust preliminary sales for the fourth quarter and the full year of 2024. The company's fourth-quarter sales ranged between $100 million to $103 million, with full-year sales between $177 million to $180 million. These figures surpassed the Goldman Sachs and FactSet consensus estimates. Over 11,800 patients were on Madrigal's drug, Rezdiffra, by the end of 2024, marking a 74% quarter-over-quarter increase. Analysts from firms including Goldman Sachs, Evercore ISI, Oppenheimer, TD Cowen, and Piper Sandler have maintained positive ratings on Madrigal, with some adjusting their price targets. The company is also actively pursuing expansion efforts, including the anticipated approval and launch of Rezdiffra in Europe by mid-2025. These are the recent developments in Madrigal Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.